Sandoval ZJ

Language: Spanish
References: 10
Page: 207-211
PDF size: 60.20 Kb.

ABSTRACT

The term Eisenmenger Syndrome is used to refer to any systemic to pulmonary congenital communication causing pulmonary vascular obstructive disease (PVOD) severe enough as to produce bidirectional or reversed shunt. Once established, the PVOD deteriorates the quality of life and limits the survival of the patients with congenital heart disease. In the last decade, there has been a significant advance in the knowledge of the pathobiology of PVOD. Potentially important pathologic processes include: genetic abnormalities, hemodynamically-induced changes associated to shear stress, endothelial abnormalities, dysfunction of potassium channels, and extra-cellular matrix alterations. Other processes such as -in situ- thrombosis, angiogenesis, and cellular apoptosis may also be involved. The medical management of this condition has improved. The role of phlebotomy and long-term oxygen therapy is now better defined. Furthermore, as a result of a better knowledge in pathobiology, new and promising forms of pharmacological treatment have appeared, including prostacyclin analogs, such as Epoprostenol (Flolan ®) for continuous intravenous use and Trepostinil sodium (Remodulin ®) for continuous subcutaneous administration.

REFERENCES

1. Collins-NRL, Rabinovitch M: Pulmonary vascular obstructive disease. Cardiol Clin 1993; 11: 675-687.

2. Archer S, Rich S: Primary pulmonary hypertension. A vascular biology and translational research “work in progress”. Circulation 2000; 102: 2781-2791.

3. Rabinovitch M: Pulmonary hypertension: pathophysiology as a basis for clinical decision making. J of Heart and Lung Transplant 1999; 18: 1041-1053.

4. Limsuwan A, Platoshyn O, Yu Y, Rubin LJ, Rothman A, Yuan JXJ: Inhibition of K+ channel activity in human pulmonary artery smooth muscle cells by serum from patients with pulmonary hypertension secondary to congenital heart disease. Pediat Res 2001; 50: 23-28.

5. Brickner ME, Hillis LD, Lange RA: Congenital heart disease in Adults. Second of two parts. N Engl J Med 2000; 342: 334-342.

6. Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, Stone S: Eisenmenger Syndrome. Factors relating to deterioration and death. Eur Heart J 1998; 19: 1845-1855.

7. Bowyer JJ, Busst CM, Denison DM, Shinebourne EA: Effect of long-term oxygen treatment at home in children with pulmonary vascular disease. Br Heart J 1986; 55: 385-90.

8. Sandoval J, Aguirre JS, Pulido T, Martínez-Guerra ML, Santos E, Alvarado P, Rosas M, Bautista E: Nocturnal oxygen therapy in patients with the Eisenmenger Syndrome. Am J Respir Crit Care Med. En Prensa.

9. Sandoval J, Alvarado P, Martínez-Guerra ML, Gómez A, Palomar A, Meza S, Santos E, Rosas M: The effect of body position on gas exchange in Eisenmenger’s syndrome. Am J Respir Crit Care Med 1999; 159: 1070-1073.

10. Rosenzweig EB, Kerstein D, Barst RJ: Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99: 1858-1865.